12/10/2010

Medtronic's CoreValve division has secured CE Mark approval for its a valve-replacement system that can treat severe aortic stenosis without requiring patients to undergo open-heart surgery. Medtronic paid $700 million to purchase CoreValve in 2009.

Full Story:
MedCityNews.com

Related Summaries